News headlines about Arbutus Biopharma (NASDAQ:ABUS) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 43.5920815298475 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- Arbutus Biopharma (ABUS) Downgraded by ValuEngine to Sell (americanbankingnews.com)
- Arbutus Biopharma (ABUS) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Arbutus Biopharma (ABUS) Upgraded to Buy by ValuEngine (americanbankingnews.com)
- Arbutus Biopharma (ABUS) Stock Rating Lowered by ValuEngine (americanbankingnews.com)
- Arbutus Biopharma (ABUS) Cut to Sell at Zacks Investment Research (americanbankingnews.com)
ABUS stock traded down $0.15 on Thursday, reaching $5.00. 186,116 shares of the company’s stock were exchanged, compared to its average volume of 181,680. Arbutus Biopharma has a twelve month low of $3.20 and a twelve month high of $8.25. The firm has a market capitalization of $278.10, a PE ratio of -2.79 and a beta of 1.06. The company has a debt-to-equity ratio of 0.09, a current ratio of 8.85 and a quick ratio of 8.85.
ABUS has been the topic of a number of recent research reports. ValuEngine raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a report on Monday. Zacks Investment Research lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, January 18th. BidaskClub raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. Wedbush lowered Arbutus Biopharma from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $9.00 to $6.00 in a report on Monday, March 19th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Arbutus Biopharma has a consensus rating of “Hold” and an average target price of $12.38.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.